跳至主要内容
临床试验/ISRCTN11720855
ISRCTN11720855已完成未知

A multi-center prospective observational clinical study to evaluate HF10™ therapy in patients with chronic intractable predominant leg pain

evro Corp0 个研究点目标入组 90 人开始时间: 2017年2月24日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • 1. Predominant leg pain either idiopathic in origin or from failed back surgery syndrome which has been refractory to conservative therapy for a minimum of 3 months
  • 2. Average leg pain intensity of = 5 out of 10 cm on the Visual Analog Scale (VAS) at enrollment
  • 3. Average leg pain intensity > average back pain intensity on the Visual Analog Scale (VAS) by 2 cm at enrollment
  • 4. Neuropathic pain as clinically determined by the investigator
  • 5. On stable pain medications, as determined by the Investigator, for at least 4 weeks prior to the Baseline Visit
  • 6. Be an appropriate candidate for HF10 therapy
  • 7. At least 18 years of age at time of enrollment
  • 8. Willing and capable of giving written informed consent prior to any study -related assessment
  • 9. Was evaluated at the investigational site at least once prior to screen for the pain condition related to the study
  • 10. Willing and able to comply with study-related requirements, assessments and visits
  • 11. Capable of subjective evaluation, able to read and understand English-written questionnaires, and able to read, understand and sign the written inform consent in English

排除标准

  • 1. A medical condition or pain in other area(s), not intended to be treated with SCS, that could interfere with study assessments, accurate pain reporting, and/or confound evaluation of study endpoints
  • 2. Evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance of intervention and/or ability to evaluate treatment outcome, as determined by the investigator in consultation with a clinical psychologist if applicable
  • 3. A current diagnosis of a progressive neurological disease such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, rapidly progressive diabetic peripheral neuropathy, brain or spinal cord tumor, or severe/critical spinal stenosis
  • 4. A visceral pain in the area being treated
  • 5. A current diagnosis of a coagulation disorder, bleeding diathesis, progressive peripheral vascular disease or uncontrolled diabetes mellitus
  • 6. A diagnosis of scoliosis that precludes lead placement
  • 7. Leg pain that occurs only with weight bearing
  • 8. Benefitting within 30 days prior to enrollment from an interventional procedure and/or surgery to treat back and/or leg pain
  • 9. Existing drug pump and/or SCS system or another active implantable device such as a pacemaker (switched On or Off)
  • 10. Have a condition currently requiring or likely to require diathermy
  • 11. Metastatic malignant disease or active local malignant disease
  • 12. A life expectancy of less than 1 year
  • 13. An active systemic or local infection
  • 14. Pregnant (if female and sexually active, subject must be using a reliable form of birth control, be surgically sterile or be at least 2 years post-menopausal)
  • 15. Within 6 months of enrollment a significant untreated addiction to dependency producing medications or have been a substance abuser (including alcohol and illicit drugs)
  • 16. Concomitantly participating in another clinical study, or planned to be enrolled in another clinical study
  • 17. Involved in an injury claim under current litigation
  • 18. A pending or approved work cover claim

研究者

发起方
evro Corp

相似试验

A clinical study to evaluate HF10™ therapy in... | 临床试验